As the Indian Healthcare Sector is witnessing a number of changes for the betterment of patient safety. An amendment of Rule 3-A of the Drugs & Cosmetics Rules, 1945 by Union Health Ministry was turned down by the Drugs Technical Advisory Board (DTAB). The proposal was to announce National Institute of Biologicals (NIB) as Central Drug Laboratory for testing few vaccines line BCG vaccine. Currently CRI, Kasauli acts as the Central Drug Laboratory. The proposal of declaring NIB, Noida as Central Drug Laboratory came for discussions in the 70th annual meeting of DTAB in which after detailed deliberations the DTAB disagreed to the proposal.
The 70th meeting of meeting of DTAB was held in CDSCO Bhawan, New Delhi on August 18th 2015. The CDSCO (Central Drugs Standard Control Organisation) is the Indian national regulatory body responsible for the regulation of drugs and medical devices in India. Presently the vaccines are tested at CDL, CRI Kasauli. The DTAB was reconstituted by the Union Health Ministry in this February under section 5 of Drugs and Cosmetics Rule. Director General of health services, Dr Jagdish Prasad, is the Chairman and Drugs Controller General (India) Dr G N Singh is a member secretary of the board. To know the other members of DTAB and what happened in the meeting you could view Minutes of the 70th Meeting of Drugs Technical Advisory Board.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More